🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 71902K402 (prev. 71902K105 )
Business: Cero Therapeutics Holdings, Inc is an immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer.
Notes: June 11, 2025 -- CERo Therapeutics Holdings, Inc., )an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company’s common stock, par value $0.0001 per share..
The reverse stock split will take effect at 12:01 a.m. Eastern Time on June 13, 2025, and the Company’s Common Stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) as of the opening of trading on June 13, 2025. The CUSIP number of 71902K402
Company Contact
- CEO
- Chris Ehrlich
- CFO
- Andrew Albert Kucharchuk
- Headquarters
- 201 Haskins Way, Suite 230, South San Francisco, CA 94080
- Phone
- 650-407-2376
- Investor Relations
- investors@cero.bio